https://www.selleckchem.com/pr....oducts/l-dehydroasco
n levels. Patients who switched from risperidone to lurasidone experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety parameters experienced during the previous 12 months of treatment with risperidone. TRIAL REGISTRATION ClinicalTrials.gov NCT00641745 (Date of Registration March 24, 2008).BACKGROUND Colorectal cancer (CRC) is the second most common malignant disease and the second most common cause of cancer death in Germany. Official CRC screening starts at
Me gusta
Comentario
Compartir
